(NP (NP (NP-COOD (NP (NN Glucocorticoid) (NN receptor)) (CC and) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN 3-O-methyl-D-glucose) (NN uptake))) (PP (IN by) (NP (NNS glucocorticoids))))) (PP (IN in) (NP (NP (JJ peripheral) (NN blood) (NNS leukocytes)) (PP (IN from) (NP (JJ normal) (NNS humans))))) (: :)) (NP (NP (NN correlation)) (PP (IN between) (NP (NP-COOD (NP (NN receptor) (NN level)) (CC and) (NP (NN hormone) (NN effect))) (ADVP (FW in) (FW vitro)))) (. .)))
(S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN measured) (NP (NP (DT the) (NN glucocorticoid) (NN receptor) (NN concentration)) (PP (IN in) (NP (NP (ADJP-COOD (ADJP (JJ mononuclear)) (CC and) (ADJP (JJ polymorphonuclear))) (NNS leukocytes)) (, ,) (SBAR (WHNP-51 (NP (DT both)) (WHPP (IN of) (WHNP (WDT which)))) (S (NP-SBJ-52 (-NONE- *T*-51)) (VP (VBD were) (VP (VBN isolated) (NP (-NONE- *-52)) (PP (IN from) (NP (NP (JJ peripheral) (NN blood)) (PP (IN from) (NP (CD ten) (JJ healthy) (JJ male) (NNS volunteers)))))))))))))) (. .))
(S (PP (IN In) (NP (NN parallel))) (, ,) (NP-SBJ-53 (NP (DT the) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NN dexamethasone))) (PP (IN on) (NP (NN 3-O-methyl-D-glucose) (NN uptake)))) (VP (VBD was) (VP (VBN assayed) (NP (-NONE- *-53)) (PP (IN in) (NP (DT the) (JJ corresponding) (JJ mononuclear) (NNS leukocytes))))) (. .))
(S-COOD (S (NP-SBJ (NP (DT The) (NN glucocorticoid) (NN receptor) (NNS levels)) (PP (IN in) (NP (JJ mononuclear) (NNS leukocytes)))) (VP (VBD correlated) (PP (IN with) (NP (NP (DT those)) (PP (IN in) (NP (JJ polymorphonuclear) (NNS leukocytes))))))) (, ,) (CC and) (S (NP-SBJ (EX there)) (VP (VBD was) (NP-PRD (DT a) (JJ linear) (NN relationship)) (PP (IN between) (NP (NP (NP-COOD (NP (DT the) (JJ cellular) (NN glucocorticoid) (NN receptor) (NNS levels)) (CC and) (NP (NP (JJ glucocorticoid-mediated) (NN inhibition)) (PP (IN of) (NP (NP (DT the) (NN uptake)) (PP (IN of) (NP (NN 3-O-methyl-D-glucose)))))))) (PP (IN in) (NP (JJ mononuclear) (NNS leukocytes))))))) (. .))
(S (SBAR-TMP (WHADVP-54 (WRB When)) (S (NP-SBJ-55 (JJ mononuclear) (NNS leukocytes)) (VP (VBD were) (VP (VBN incubated) (NP (-NONE- *-55)) (PP (IN in) (DT the) (NN presence) (IN of) (NP (NN 8-bromo-cAMP))) (ADVP (-NONE- *T*-54)))))) (, ,) (S-COOD (S (NP-SBJ (JJ cellular) (NN glucocorticoid) (NN receptor) (NNS levels)) (VP (VBD increased))) (CC and) (S (NP-SBJ-56 (NP (DT a) (ADJP (RBR more) (JJ pronounced)) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NN dexamethasone)))) (VP (VBD was) (VP (VBN observed) (NP (-NONE- *-56)) (PP (IN on) (NP (NP (DT the) (NN transport)) (PP (IN of) (NP (NN 3-O-methyl-D-glucose))))))))) (. .))
(S (NP-SBJ (PRP We)) (VP (VBP conclude) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ cellular) (NN glucocorticoid) (NN receptor) (NNS levels)) (PP (IN in) (NP (JJ peripheral) (NN blood) (NNS leukocytes)))) (VP (VBP reflect) (NP (NP (ADJP (FW in) (FW vitro)) (NN responsiveness)) (PP (TO to) (NP (NP (NNS glucocorticoids)) (PP (IN in) (NP (NP (JJ mononuclear) (NNS leukocytes)) (PP (IN from) (NP (JJ healthy) (NNS males))))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP-SBJ (DT the) (JJ individual) (NN responsiveness)) (VP (MD may) (VP (VB alter) (PP-TMP (IN upon) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ cellular) (NNS levels)) (PP (IN of) (NP (NN glucocorticoid) (NN receptor))))))))))))) (. .))
